

Advancing Care in Non-Clear Cell RCC:

Optimizing ICI and TKIs

Mitigating AEs: The Importance of Multidisciplinary, Patient-Centered Care

Learning Objectives

- Identify approaches for monitoring and managing AEs associated with ICIs and TKIs in nccRCC
- Demonstrate increased knowledge in recognizing treatment-associated toxicities and strategies for coordinating multidisciplinary care to manage AEs

Treatment-Related AEs Common to TKIs

Common TRAEs of any grade

Hypophosphatemia

Commonly observed with
Cabozantinib¹⁻³

Any TRAE	Grade 3-4 TRAEs
13%-30%	13%-33%

Hand Foot Syndrome

Commonly observed with
Cabozantinib¹⁻³

Any TRAE	Grade 3-4 TRAEs
21%-68%	3%-21%

Diarrhea

Commonly observed with
Cabozantinib¹⁻³ • Lenvatinib⁴
Sunitinib^{1,5} • Savolitinib⁵

Any TRAE	Grade 3-4 TRAEs
9%-90%	0%-15%

Hypertension

Commonly observed with
Sunitinib^{1,5}
Lenvatinib + Pembrolizumab⁴

Any TRAE	Grade 3-4 TRAEs
22%-57%	15%-23%

The most common grade 3-4 TRAEs associated with TKIs are¹⁻⁵:

- Hypophosphatemia
- Hand foot syndrome
- Hypertension
- Increased AST/ALT

Provided by



The
France
Foundation



KidneyCancerAssociation™
Unstoppable Together.

Advancing Care in Non-Clear Cell RCC:

Optimizing ICI and TKIs

Mitigating AEs: The Importance of Multidisciplinary, Patient-Centered Care


Treatment-Related AEs Common to ICIs

Common TRAEs of any grade^{6,7}

- Diarrhea
- Fatigue
- Hypothyroidism
- Pruritus

Grade 3-4 TRAEs...^{6,7}

- Are less common with ICIs than with TKIs
- Include fever (7%), rash/skin toxicity (0%-5%), fatigue (2%), and diarrhea (2%)



AE Mitigation and Multidisciplinary Care

- A multidisciplinary approach to AE management is ideal but not always possible⁸
- Strategies to enhance multidisciplinary care include:
 - Proactive diagnosis and management of AEs
 - High suspicion of immunotherapy-related AEs, even after treatment discontinuation
- [Kidney Cancer Association](#) offers multilingual patient resources on treatment-related AEs⁹

Provided by



The
France
Foundation



KidneyCancerAssociation™

Unstoppable Together.

Advancing Care in Non-Clear Cell RCC: Optimizing ICI and TKIs

Mitigating AEs: The Importance of Multidisciplinary, Patient-Centered Care

Key Takeaways

- The safety profile for TKI + ICI regimens is between nccRCC and ccRCC
- AEs commonly associated with TKIs include hand foot syndrome, hypophosphatemia, hypertension, and diarrhea
- Savolitinib bears unique AEs (e.g., edema, muscle pain)
- The safety profile for zanzalitinib may be milder than other TKIs
- The KCA maintains a website with extensive side effect resources for patients being treated for nccRCC
- A team-based approach allows for personalized care, optimizing treatment strategies while minimizing risks and complications

References

1. Barata P, Tangen C, Plets M, et al. Final overall survival analysis of S1500: a randomized, phase II study comparing sunitinib with cabozantinib, crizotinib, and Savolitinib in advanced papillary renal cell carcinoma. *J Clin Oncol*. Nov 20 2024;42(33):3911-3916. doi:10.1200/JCO.24.00767. <https://pubmed.ncbi.nlm.nih.gov/39255440/>
2. Fitzgerald KN, Lee CH, Voss MH, et al. Cabozantinib plus nivolumab in patients with non-clear cell renal cell carcinoma: updated results from a phase 2 trial. *Eur Urol*. Aug 2024;86(2):90-94. doi:10.1016/j.eururo.2024.04.025. <https://pubmed.ncbi.nlm.nih.gov/38782695/>
3. Pal SK, McGregor B, Suarez C, et al. Cabozantinib in combination with atezolizumab for advanced renal cell carcinoma: results from the COSMIC-021 study. *J Clin Oncol*. Nov 20 2021;39(33):3725-3736. doi:10.1200/JCO.21.00939. <https://pubmed.ncbi.nlm.nih.gov/34491815/>
4. Albiges L, Gurney H, Atduiev V, et al. Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial. *Lancet Oncol*. Aug 2023;24(8):881-891. doi:10.1016/S1470-2045(23)00276-0. <https://pubmed.ncbi.nlm.nih.gov/37451291/>
5. Choueiri TK, Plimack E, Arkenau HT, et al. Biomarker-based phase II trial of savolitinib in patients with advanced papillary renal cell cancer. *J Clin Oncol*. Sep 10 2017;35(26):2993-3001. doi:10.1200/JCO.2017.72.2967. <https://pubmed.ncbi.nlm.nih.gov/28644771/>
6. Koshkin VS, Barata PC, Zhang T, et al. Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma. *J Immunother Cancer*. Jan 29 2018;6(1):9. doi:10.1186/s40425-018-0319-9. <https://pubmed.ncbi.nlm.nih.gov/29378660/>
7. McDermott DF, Lee JL, Ziobro M, et al. Open-label, single-arm, phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced non-clear cell renal cell carcinoma. *J Clin Oncol*. Mar 20 2021;39(9):1029-1039. doi:10.1200/JCO.20.02365. <https://pubmed.ncbi.nlm.nih.gov/33529058/>
8. National Comprehensive Cancer Network. *NCCN Guidelines: Management of Immunotherapy-Related Toxicities. Version 1.2025*. 2025. <https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1486>
9. Kidney Cancer Association. <https://www.kidneycancer.org>

Provided by



The
France
Foundation



KidneyCancerAssociation™
Unstoppable Together.